Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease

A summary of the Southwest Oncology Group experience

Evan M Hersh, B. S. Metch, F. M. Muggia, T. D. Brown, R. P. Whitehead, G. T. Budd, J. J. Rinehart, E. D. Crawford, J. D. Bonnet, B. C. Behrens

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

From June 1988 to November 1990 the Southwest Oncology Group initiated nine protocols for the phase II evaluation of recombinant human tumor necrosis factor alpha (rhuTNFα) in cancer patients. Patients with diverse metastatic malignancies including breast, colon, gastric, pancreatic, endometrial, and bladder cancers, as well as multiple myeloma and various sarcomas received 150 μg/m2 of rhuTNFα daily for 5 days every other week. Of 147 patients entered in the study, 127 were eligible and were evaluated for toxicity and response. Of 124 patients known to have completed treatment, 92 (74%) went off study for progression, 21 (17%) for toxicity, and 12 (10%) for other causes, mainly that of worsening medical condition. Thirteen percent of patients experienced grade 4 or fatal toxicity. The most serious toxicities were pulmonary failure and coagulopathies. The predominant grade 3 toxicities were symptomatic (chills, fever, malaise, headache, myalgia, and nausea or vomiting). Only one partial remission was seen in a patient with metastatic bladder cancer lasting 4 months (rate 0.8%, exact 95% confidence interval 0-4%). At the study dose and schedule, rhuTNFα does not appear to have significant antitumor activity. The biological basis for this finding is discussed.

Original languageEnglish (US)
Pages (from-to)426-431
Number of pages6
JournalJournal of Immunotherapy
Volume10
Issue number6
StatePublished - 1991

Fingerprint

Tumor Necrosis Factor-alpha
Urinary Bladder Neoplasms
Chills
Myalgia
Endometrial Neoplasms
Multiple Myeloma
Pancreatic Neoplasms
Sarcoma
Colonic Neoplasms
Nausea
Stomach Neoplasms
Vomiting
Headache
human TNF protein
Neoplasms
Appointments and Schedules
Fever
Confidence Intervals
Breast Neoplasms
Lung

Keywords

  • Antitumor activity
  • Metastatic malignancy
  • Multiple myeloma
  • Recombinant human tumor necrosis factor alpha
  • Sarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Pharmacology

Cite this

Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease : A summary of the Southwest Oncology Group experience. / Hersh, Evan M; Metch, B. S.; Muggia, F. M.; Brown, T. D.; Whitehead, R. P.; Budd, G. T.; Rinehart, J. J.; Crawford, E. D.; Bonnet, J. D.; Behrens, B. C.

In: Journal of Immunotherapy, Vol. 10, No. 6, 1991, p. 426-431.

Research output: Contribution to journalArticle

Hersh, EM, Metch, BS, Muggia, FM, Brown, TD, Whitehead, RP, Budd, GT, Rinehart, JJ, Crawford, ED, Bonnet, JD & Behrens, BC 1991, 'Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: A summary of the Southwest Oncology Group experience', Journal of Immunotherapy, vol. 10, no. 6, pp. 426-431.
Hersh, Evan M ; Metch, B. S. ; Muggia, F. M. ; Brown, T. D. ; Whitehead, R. P. ; Budd, G. T. ; Rinehart, J. J. ; Crawford, E. D. ; Bonnet, J. D. ; Behrens, B. C. / Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease : A summary of the Southwest Oncology Group experience. In: Journal of Immunotherapy. 1991 ; Vol. 10, No. 6. pp. 426-431.
@article{dee4e7106c8e4529be65be48470d1639,
title = "Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: A summary of the Southwest Oncology Group experience",
abstract = "From June 1988 to November 1990 the Southwest Oncology Group initiated nine protocols for the phase II evaluation of recombinant human tumor necrosis factor alpha (rhuTNFα) in cancer patients. Patients with diverse metastatic malignancies including breast, colon, gastric, pancreatic, endometrial, and bladder cancers, as well as multiple myeloma and various sarcomas received 150 μg/m2 of rhuTNFα daily for 5 days every other week. Of 147 patients entered in the study, 127 were eligible and were evaluated for toxicity and response. Of 124 patients known to have completed treatment, 92 (74{\%}) went off study for progression, 21 (17{\%}) for toxicity, and 12 (10{\%}) for other causes, mainly that of worsening medical condition. Thirteen percent of patients experienced grade 4 or fatal toxicity. The most serious toxicities were pulmonary failure and coagulopathies. The predominant grade 3 toxicities were symptomatic (chills, fever, malaise, headache, myalgia, and nausea or vomiting). Only one partial remission was seen in a patient with metastatic bladder cancer lasting 4 months (rate 0.8{\%}, exact 95{\%} confidence interval 0-4{\%}). At the study dose and schedule, rhuTNFα does not appear to have significant antitumor activity. The biological basis for this finding is discussed.",
keywords = "Antitumor activity, Metastatic malignancy, Multiple myeloma, Recombinant human tumor necrosis factor alpha, Sarcoma",
author = "Hersh, {Evan M} and Metch, {B. S.} and Muggia, {F. M.} and Brown, {T. D.} and Whitehead, {R. P.} and Budd, {G. T.} and Rinehart, {J. J.} and Crawford, {E. D.} and Bonnet, {J. D.} and Behrens, {B. C.}",
year = "1991",
language = "English (US)",
volume = "10",
pages = "426--431",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease

T2 - A summary of the Southwest Oncology Group experience

AU - Hersh, Evan M

AU - Metch, B. S.

AU - Muggia, F. M.

AU - Brown, T. D.

AU - Whitehead, R. P.

AU - Budd, G. T.

AU - Rinehart, J. J.

AU - Crawford, E. D.

AU - Bonnet, J. D.

AU - Behrens, B. C.

PY - 1991

Y1 - 1991

N2 - From June 1988 to November 1990 the Southwest Oncology Group initiated nine protocols for the phase II evaluation of recombinant human tumor necrosis factor alpha (rhuTNFα) in cancer patients. Patients with diverse metastatic malignancies including breast, colon, gastric, pancreatic, endometrial, and bladder cancers, as well as multiple myeloma and various sarcomas received 150 μg/m2 of rhuTNFα daily for 5 days every other week. Of 147 patients entered in the study, 127 were eligible and were evaluated for toxicity and response. Of 124 patients known to have completed treatment, 92 (74%) went off study for progression, 21 (17%) for toxicity, and 12 (10%) for other causes, mainly that of worsening medical condition. Thirteen percent of patients experienced grade 4 or fatal toxicity. The most serious toxicities were pulmonary failure and coagulopathies. The predominant grade 3 toxicities were symptomatic (chills, fever, malaise, headache, myalgia, and nausea or vomiting). Only one partial remission was seen in a patient with metastatic bladder cancer lasting 4 months (rate 0.8%, exact 95% confidence interval 0-4%). At the study dose and schedule, rhuTNFα does not appear to have significant antitumor activity. The biological basis for this finding is discussed.

AB - From June 1988 to November 1990 the Southwest Oncology Group initiated nine protocols for the phase II evaluation of recombinant human tumor necrosis factor alpha (rhuTNFα) in cancer patients. Patients with diverse metastatic malignancies including breast, colon, gastric, pancreatic, endometrial, and bladder cancers, as well as multiple myeloma and various sarcomas received 150 μg/m2 of rhuTNFα daily for 5 days every other week. Of 147 patients entered in the study, 127 were eligible and were evaluated for toxicity and response. Of 124 patients known to have completed treatment, 92 (74%) went off study for progression, 21 (17%) for toxicity, and 12 (10%) for other causes, mainly that of worsening medical condition. Thirteen percent of patients experienced grade 4 or fatal toxicity. The most serious toxicities were pulmonary failure and coagulopathies. The predominant grade 3 toxicities were symptomatic (chills, fever, malaise, headache, myalgia, and nausea or vomiting). Only one partial remission was seen in a patient with metastatic bladder cancer lasting 4 months (rate 0.8%, exact 95% confidence interval 0-4%). At the study dose and schedule, rhuTNFα does not appear to have significant antitumor activity. The biological basis for this finding is discussed.

KW - Antitumor activity

KW - Metastatic malignancy

KW - Multiple myeloma

KW - Recombinant human tumor necrosis factor alpha

KW - Sarcoma

UR - http://www.scopus.com/inward/record.url?scp=0025792319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025792319&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 426

EP - 431

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 6

ER -